Taniwaki, Masafumi

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 1,322

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., Aikawa, K., Tsushita, K., et al. (2004) · Annals of Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 108

Novel loss‐of‐function mutations of the haematopoiesis‐related transcription factor, acute myeloid leukaemia 1/runt‐related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome

Nakao, M., Horiike, S., Fukushima‐Nakase, Y., Nishimura, M., Fujita, Y., Taniwaki, M., & Okuda, T. (2004) · British Journal of Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 34

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., et al. (2022) · International Journal of Molecular Sciences

Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 11